使用双态马尔科夫链的阿尔茨海默病进展的随机模型
1Department of Nutrition, Case Western Reserve School of Medicine, Cleveland, Ohio, US.
bioRxiv : the preprint server for biology
|July 10, 2023
概括
这项研究在阿尔茨海默病模型中引入了随机性,揭示了随机过程加速神经元死亡,并减缓了诸如Tau和Amyloid beta等关键蛋白质的产生.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 数学建模的数学建模
背景情况:
- 哈奥和弗里德曼模型 (2016) 使用对阿尔茨海默病 (AD) 进展的微分方程.
- 这种决定性模型没有考虑AD固有的分子和细胞随机性.
结论:
- 随机模型揭示了对阿尔茨海默病进展动态的关键见解.
- 不恒定的反应速率和时间步骤显著影响疾病的整体轨迹.
- 这种方法提供了对阿尔茨海默病机制的更全面的了解.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
